{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T02:12:06Z","timestamp":1783476726705,"version":"3.55.0"},"reference-count":18,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T00:00:00Z","timestamp":1772582400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Immune checkpoint inhibitors (ICIs) are known to cause a wide spectrum of immune-related adverse events (irAEs). Among these, eosinophilic fasciitis (EF) is a rare, fibrosing disorder causing inflammatory infiltration of subcutaneous fat and fascia. It is characterized clinically by edema and subsequent induration and tightening of the skin and subcutaneous tissues. Several case reports have documented EF secondary to ICIs in patients on active treatment. Herein, we present two cases of delayed EF following treatment cessation with avelumab for metastatic urothelial carcinoma (Case 1) and following adjuvant nivolumab completion for stage IIIC melanoma (Case 2). Both patients had typical exam findings including erythema\/edema of the extremities and trunk and diffuse thickening of subcutaneous fat and fascia, leading to severe respiratory restriction in Case 1. Both patients were diagnosed with EF by full-thickness skin biopsy showing sclerosis and lymphocytic infiltration of the subcutaneous fat and\/or fascia. Only one of the two patients presented with definite eosinophilia. Both cases were treated with glucocorticoids and had early recurrence of symptoms post steroid taper, necessitating subsequent protracted steroid and steroid sparing agent use. Overall, we demonstrate the importance of considering delayed irAEs, specifically autoimmune fibrotic skin diseases even when ICI therapy has been discontinued. We underscore the need for collaboration between oncology and rheumatology as the scope of ICI treatments for cancer continues to expand.<\/jats:p>","DOI":"10.3389\/fonc.2026.1613243","type":"journal-article","created":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T05:40:51Z","timestamp":1772602851000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Two case reports of eosinophilic fasciitis with onset after immune checkpoint inhibitor cessation"],"prefix":"10.3389","volume":"16","author":[{"given":"Christopher F.","family":"Theriau","sequence":"first","affiliation":[{"name":"Division of Medical Oncology, Department of Medicine, The Ottawa Hospital Cancer Centre","place":["Ottawa, ON, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"Maltez","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Medicine, The Ottawa Hospital","place":["Ottawa, ON, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niloufar","family":"Hosseini","sequence":"additional","affiliation":[{"name":"Division of Diagnostic and Molecular Pathology, Department of Laboratory Medicine, The Ottawa Hospital","place":["Ottawa, ON, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Petkiewicz","sequence":"additional","affiliation":[{"name":"Division of Diagnostic and Molecular Pathology, Department of Laboratory Medicine, The Ottawa Hospital","place":["Ottawa, ON, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinni","family":"Song","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Medicine, The Ottawa Hospital Cancer Centre","place":["Ottawa, ON, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Ong","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Medicine, The Ottawa Hospital Cancer Centre","place":["Ottawa, ON, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1136\/annrheumdis-2020-217139","article-title":"EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors","volume":"80","author":"Kostine","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"B2","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1007\/s11926-017-0700-6","article-title":"Eosinophilic fasciitis: an updated review on diagnosis and treatment","volume":"19","author":"Mazori","year":"2017","journal-title":"Curr Rheumatol Rep"},{"key":"B3","article-title":"Diffuse fasciitis with hypergammaglobulinemia and eosinophilia: a new syndrome","volume":"11","author":"Shulman","year":"1984","journal-title":"J Rheumatol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2014.01.019","article-title":"Diagnosis and classification of eosinophilic fasciitis","volume":"13","author":"Pinal-Fernandez","year":"2014","journal-title":"Autoimmun Rev"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.14160","article-title":"Diagnostic criteria, severity classification and guidelines of eosinophilic fasciitis","volume":"45","author":"Jinnin","year":"2018","journal-title":"J Dermatol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2024.03.015","article-title":"Characteristics and management of sclerosing skin diseases during immune checkpoint inhibitor therapy: An evidence-based review","volume":"91","author":"Sood","year":"2024","journal-title":"J Am Acad Dermatol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"259","DOI":"10.3390\/ph16020259","article-title":"Checkpoint inhibitor-associated scleroderma and scleroderma mimics","volume":"16","author":"Macklin","year":"2023","journal-title":"Pharm Basel Switz"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2021.05.030","article-title":"Drug-induced eosinophilic fasciitis: A dual pharmacovigilance analysis","volume":"86","author":"Teboul","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2019-0508","article-title":"Eosinophilic fasciitis following checkpoint inhibitor therapy: four cases and a review of literature","volume":"25","author":"Chan","year":"2020","journal-title":"Oncologist"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2018.05.002","article-title":"Rheumatic immune-related adverse events in patients on anti-PD-1 inhibitors: Fasciitis with myositis syndrome as a new complication of immunotherapy","volume":"17","author":"Narv\u00e1ez","year":"2018","journal-title":"Autoimmun Rev"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-15-0186","article-title":"Eosinophilic fasciitis and acute encephalopathy toxicity from pembrolizumab treatment of a patient with metastatic melanoma","volume":"4","author":"Khoja","year":"2016","journal-title":"Cancer Immunol Res"},{"key":"B12","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1186\/s40425-019-0645-6","article-title":"Delayed immune-related events (DIRE) after discontinuation of immunotherapy: diagnostic hazard of autoimmunity at a distance","volume":"7","author":"Couey","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.36.15_suppl.e15074","article-title":"Delayed toxicities with anti-PD-1 and anti-PDL-1 immune checkpoint inhibitors (ICIs)","volume":"36","author":"Shah","year":"2018","journal-title":"J Clin Oncol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1007\/s11886-021-01530-2","article-title":"Mechanisms driving immune-related adverse events in cancer patients treated with immune checkpoint inhibitors","volume":"23","author":"Lee","year":"2021","journal-title":"Curr Cardiol Rep"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2018.10.012","article-title":"Molecular mimicry and autoimmunity","volume":"95","author":"Rojas","year":"2018","journal-title":"J Autoimmun"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185X.13770","article-title":"Baseline characteristics and long-term outcomes of eosinophilic fasciitis in 89 patients seen at a single center over 20 years","volume":"23","author":"Mango","year":"2020","journal-title":"Int J Rheum Dis"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2015.3648","article-title":"Epidemiology and treatment of eosinophilic fasciitis: an analysis of 63 patients from 3 tertiary care centers","volume":"152","author":"Wright","year":"2016","journal-title":"JAMA Dermatol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ker366","article-title":"Eosinophilic fasciitis (Shulman disease): new insights into the therapeutic management from a series of 34 patients","volume":"51","author":"Lebeaux","year":"2012","journal-title":"Rheumatol Oxf Engl"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1613243\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T05:40:52Z","timestamp":1772602852000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1613243\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,4]]},"references-count":18,"alternative-id":["10.3389\/fonc.2026.1613243"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1613243","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,4]]},"article-number":"1613243"}}